✦ LIBER ✦

99mTc Labeled Biotin Conjugate in a Tumor “Pretargeting” Approach with Monoclonal Antibodies

✍ Scribed by Dipl.-Chem. Peter Koch; Prof. Dr. Helmut Robert Mäcke

Publisher: John Wiley and Sons
Year: 1992
Tongue: English
Weight: 357 KB
Volume: 31
Category: Article
ISSN: 0044-8249
DOI: 10.1002/anie.199215071

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

99m-technetium labelling of a tumor asso

99m-technetium labelling of a tumor associated murine monoclonal antibody for immunoscintigraphic studies in man

✍ Dr. Spyridon C. Archimandritis; Julia Malamitsi; Elias Belkas; Alexandra D. Varv 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 513 KB

## Abstract The present study refers to the preparation of a 99m‐Technetium labelled murine monoclonal antibody for clinical application. The monoclonal antibody was incubated with a 20fold molar excess of 2‐iminothiolane. The free thiol groups created, were capable of binding reduced technetium. L

A pilot pharmacokinetic and immunoscinti

A pilot pharmacokinetic and immunoscintigraphic study with the technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors

✍ Giuliano Mariani; Arben Lasku; Antonio Pau; Giuseppe Villa; Cinzia Motta; Giusep 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB 👁 2 views

tumor targeting potential in vivo of radiolabeled BC-1, an immunoglobulin (Ig)G 1 monoclonal antibody (MoAb) that recognizes the human fibronectin isoform (B / ) containing

Toxicity-reducing potential of extracorp

Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model

✍ Rune Nilsson; Linda Mårtensson; Sophie E. Eriksson; Hans-Olov Sjögren; Jan Tennv 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 352 KB

Assessment of antibodies to double-stran

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials

✍ P. J. Charles; R. J. T. Smeenk; J. De Jong; M. Feldmann; R. N. Maini 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 2 views

Objective. To compare the incidence of antidouble-stranded DNA (anti-dsDNA) antibodies in rheumatoid arthritis (RA) patients receiving either single or multiple doses of a chimeric anti-tumor necrosis factor ␣ (anti-TNF␣) antibody or placebo infusions, with or without methotrexate, in open-label, ra